# S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery

> **NCT02562716** · PHASE2 · COMPLETED · sponsor: **SWOG Cancer Research Network** · enrollment: 147 (actual)

## Conditions studied

- Pancreatic Adenocarcinoma
- Resectable Pancreatic Carcinoma

## Interventions

- **DRUG:** Fluorouracil
- **DRUG:** Gemcitabine Hydrochloride
- **DRUG:** Irinotecan Hydrochloride
- **DRUG:** Oxaliplatin
- **DRUG:** Paclitaxel Albumin-Stabilized Nanoparticle Formulation
- **PROCEDURE:** Pancreatectomy

## Key facts

- **NCT ID:** NCT02562716
- **Lead sponsor:** SWOG Cancer Research Network
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01-06
- **Primary completion:** 2020-05-31
- **Final completion:** 2022-09-26
- **Target enrollment:** 147 (ACTUAL)
- **Last updated:** 2022-10-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02562716

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02562716, "S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02562716. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*